340 related articles for article (PubMed ID: 26823838)
1. miR-21 expression predicts prognosis in diffuse large B-cell lymphoma.
Li J; Fu R; Yang L; Tu W
Int J Clin Exp Pathol; 2015; 8(11):15019-24. PubMed ID: 26823838
[TBL] [Abstract][Full Text] [Related]
2. Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone.
Wu PY; Zhang XD; Zhu J; Guo XY; Wang JF
Hum Pathol; 2014 Aug; 45(8):1664-73. PubMed ID: 24931464
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
Yang JM; Jang JY; Jeon YK; Paik JH
J Transl Med; 2018 Jun; 16(1):162. PubMed ID: 29890998
[TBL] [Abstract][Full Text] [Related]
4. Low expression of miRNA-224 predicts poor clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP.
Ni H; Wang X; Liu H; Tian F; Song G
Biomarkers; 2015; 20(4):253-7. PubMed ID: 26301883
[TBL] [Abstract][Full Text] [Related]
5. LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy.
Peng W; Wu J; Feng J
Clin Exp Med; 2017 Feb; 17(1):1-8. PubMed ID: 26475621
[TBL] [Abstract][Full Text] [Related]
6. Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients.
Song G; Gu L; Li J; Tang Z; Liu H; Chen B; Sun X; He B; Pan Y; Wang S; Cho WC
Ann Hematol; 2014 Oct; 93(10):1735-43. PubMed ID: 24858372
[TBL] [Abstract][Full Text] [Related]
7. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
8. The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma.
Hao X; Wei X; Huang F; Wei Y; Zeng H; Xu L; Zhou Q; Feng R
PLoS One; 2015; 10(5):e0126615. PubMed ID: 25974110
[TBL] [Abstract][Full Text] [Related]
9. Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.
Yoon JH; Kim JW; Jeon YW; Lee SE; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Park CW; Cho SG
Korean J Intern Med; 2015 May; 30(3):362-71. PubMed ID: 25995667
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):671-9. PubMed ID: 26361646
[TBL] [Abstract][Full Text] [Related]
11. High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma.
Marques SC; Ranjbar B; Laursen MB; Falgreen S; Bilgrau AE; Bødker JS; Jørgensen LK; Primo MN; Schmitz A; Ettrup MS; Johnsen HE; Bøgsted M; Mikkelsen JG; Dybkær K
Exp Hematol; 2016 Apr; 44(4):238-46.e2. PubMed ID: 26854484
[TBL] [Abstract][Full Text] [Related]
12. High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era.
Song MK; Yang DH; Lee GW; Lim SN; Shin S; Pak KJ; Kwon SY; Shim HK; Choi BH; Kim IS; Shin DH; Kim SG; Oh SY
Leuk Res; 2016 Mar; 42():1-6. PubMed ID: 26851438
[TBL] [Abstract][Full Text] [Related]
13. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM
Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569
[TBL] [Abstract][Full Text] [Related]
14. MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP.
Alencar AJ; Malumbres R; Kozloski GA; Advani R; Talreja N; Chinichian S; Briones J; Natkunam Y; Sehn LH; Gascoyne RD; Tibshirani R; Lossos IS
Clin Cancer Res; 2011 Jun; 17(12):4125-35. PubMed ID: 21525173
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
16. Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study.
Marchesi F; Regazzo G; Palombi F; Terrenato I; Sacconi A; Spagnuolo M; Donzelli S; Marino M; Ercolani C; Di Benedetto A; Blandino G; Ciliberto G; Mengarelli A; Rizzo MG
J Exp Clin Cancer Res; 2018 May; 37(1):95. PubMed ID: 29716630
[TBL] [Abstract][Full Text] [Related]
17. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
[TBL] [Abstract][Full Text] [Related]
18. Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B-cell lymphoma patients with and without rheumatic disease.
Brauner S; Zhou W; Backlin C; Green TM; Folkersen L; Ivanchenko M; Löfström B; Xu-Monette ZY; Young KH; Møller Pedersen L; Boe Møller M; Sundström C; Enblad G; Baecklund E; Wahren-Herlenius M
J Intern Med; 2015 Sep; 278(3):323-32. PubMed ID: 25880119
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma.
Yue X; Lan F; Hu M; Pan Q; Wang Q; Wang J
J Neurosurg; 2016 Jan; 124(1):122-8. PubMed ID: 26230475
[TBL] [Abstract][Full Text] [Related]
20. Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin.
Sun N; Wang CY; Sun YQ; Ruan YJ; Huang YY; Su T; Zhou XH; Huang H; Guo WJ; He MQ; Yao RX; Lin XJ
Biomed Pharmacother; 2018 Oct; 106():267-274. PubMed ID: 29966970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
